Latest Therapeutics News

Page 32 of 48
INOVIQ Limited has responded to ASX queries defending its announcement that its new CAR-NK-EV treatment killed 88% of breast and lung cancer cells in vitro, confirming compliance with disclosure rules and providing detailed study data.
Ada Torres
Ada Torres
23 June 2025
Microba Life Sciences announces a $12.5 million equity raise, including a strategic $8.3 million investment from Sonic Healthcare, aiming to fuel growth in the UK and achieve regional break-even by FY26.
Ada Torres
Ada Torres
23 June 2025
Tryptamine Therapeutics has secured ethics approval to begin a pioneering clinical trial of TRP-8803, an IV-infused psilocin treatment, targeting adult patients with Binge Eating Disorder. The trial aims to evaluate safety and efficacy, with initial results expected by the end of 2025.
Ada Torres
Ada Torres
23 June 2025
PYC Therapeutics has gained FDA alignment on the design of its pivotal Phase 2/3 trial for VP-001, a promising treatment for the rare childhood blindness RP11. The regulator accepted the trial’s sham control arm and primary endpoints, setting the stage for a critical next step toward drug approval.
Ada Torres
Ada Torres
23 June 2025
Optiscan Imaging Ltd has entered a five-year exclusive collaboration with Long Grove Pharmaceuticals to jointly develop new clinical applications for the fluorescein drug AK-FLOUR®, supporting US clinical trials and FDA regulatory submissions for Optiscan’s InVue® surgical device.
Ada Torres
Ada Torres
23 June 2025
Immutep reports promising Phase I results for IMP761, a novel LAG-3 agonist antibody demonstrating significant T cell inhibition and a clean safety profile, advancing hopes for new autoimmune disease treatments.
Ada Torres
Ada Torres
23 June 2025
Argenica Therapeutics has won up to $1.5 million in non-dilutive government funding to support its late-stage clinical trial of ARG-007, a promising treatment for acute ischaemic stroke.
Ada Torres
Ada Torres
20 June 2025
Neurizon Therapeutics reveals that its lead drug candidate NUZ-001 and its metabolite effectively penetrate the blood-brain barrier and reverse pathological protein aggregation linked to ALS, marking a critical step forward in neurodegenerative disease treatment.
Ada Torres
Ada Torres
20 June 2025
Bioxyne Limited has upgraded its FY2025 revenue guidance to approximately $28 million, driven by strong domestic performance and significant progress in European and UK markets. The company also advances its psychedelic medicines pipeline, positioning itself for sustained growth.
Ada Torres
Ada Torres
19 June 2025
NeuroScientific Biopharmaceuticals reveals compelling clinical evidence supporting its StemSmart MSC therapy for severe steroid-refractory graft versus host disease, advancing its strategic acquisition plans.
Ada Torres
Ada Torres
19 June 2025
Amplia Therapeutics has announced a second confirmed complete response in its ACCENT trial for advanced pancreatic cancer, a notably rare achievement in this challenging disease.
Ada Torres
Ada Torres
19 June 2025
Opyl Limited’s AI platform TrialKey has partnered with UK insurer Innovatrix to launch a pioneering parametric insurance product that protects biotech firms from the financial risks of clinical trial failures.
Ada Torres
Ada Torres
18 June 2025